Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 228 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... February 8, 2022 Thinking outside the chromosome – how ecDNA is challenging conventional thinking November 11, 2022 Cómo puede ayudar la terapia del piso pélvico a las personas... December 13, 2022 Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary... August 10, 2026 Load more HOT NEWS For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... Building Your Fort of Support: Tips from a Breast Cancer Social...
